Wedbush analyst Andreas Argyrides reiterated a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price target of $72.00. The company's shares closed last Wednesday at $22.81. According to TipRanks.com, Argyrides ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.9% and a 22.7% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and BioMarin Pharmaceutical. Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $69.00.
https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-albireo-pharma-albo-2?utm_source=advfn.com&utm_medium=referral
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Sep 2022 bis Okt 2022 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Okt 2021 bis Okt 2022 Click Here for more Albireo Pharma Charts.